Induction therapy with paclitaxel and bevacizumab followed by switch maintenance therapy with eribulin in Japanese patients with HER2-negative metastatic breast cancer: a multicent...

by Kenichi Inoue, Jun Ninomiya, Tsuyoshi Saito, Kei Kimizuka, Masafumi Kurosumi
Published 2018-06-01

Power of PgR expression as a prognostic factor for ER-positive/HER2-negative breast cancer patients at intermediate risk classified by the Ki67 labeling index

by Sasagu Kurozumi, Hiroshi Matsumoto, Yuji Hayashi, Katsunori Tozuka, Kenichi Inoue, Jun Horiguchi, Izumi Takeyoshi, Tetsunari Oyama, Masafumi Kurosumi
Published 2017-05-01

Utility of Ki67 labeling index, cyclin D1 expression, and ER-activity level in postmenopausal ER-positive and HER2-negative breast cancer with neoadjuvant chemo-endocrine therapy.

by Sasagu Kurozumi, Yuri Yamaguchi, Hiroshi Matsumoto, Masafumi Kurosumi, Shin-Ichi Hayashi, Takaaki Fujii, Jun Horiguchi, Ken Shirabe, Kenichi Inoue
Published 2019-01-01

Impact of combining the progesterone receptor and preoperative endocrine prognostic index (PEPI) as a prognostic factor after neoadjuvant endocrine therapy using aromatase inhibito...

by Sasagu Kurozumi, Hiroshi Matsumoto, Kenichi Inoue, Katsunori Tozuka, Yuji Hayashi, Masafumi Kurosumi, Tetsunari Oyama, Takaaki Fujii, Jun Horiguchi, Hiroyuki Kuwano
Published 2018-01-01